| Autor: |
Jin-Cheng Tian, Hui Liu, Lun-Jie Yan, Zi-Niu Ding, Cheng-Long Han, Bao-Wen Tian, Si-Yu Tan, Zhao-Ru Dong, Dong-Xu Wang, Jun-Shuai Xue, Xin-Cheng Mao, Yu-Chuan Yan, Tao Li |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Clinical and Experimental Medicine. |
| ISSN: |
1591-9528 |
| DOI: |
10.1007/s10238-022-00938-6 |
| Popis: |
The introduction of immune checkpoint inhibitors (ICIs) has reshaped the therapy of hepatocellular carcinoma (HCC). ICIs are a novel therapy with frequent adverse events (AEs), including treatment-related adverse events (trAEs) and immune-related adverse events (irAEs). However, no comprehensive overview of the toxicity spectrum of ICIs in HCC patients has been provided. Electronic databases were searched to identify eligible studies. A meta-analysis of the incidence rate of AEs in HCC patients treated with ICIs was performed. Lastly, the prognostic value of irAEs in HCC patients treated with ICIs was verified. Forty-seven studies with 6472 participations met the inclusion criteria. The pooled all-grade trAEs incidence rate was 83.4% (95% confidence interval [95% CI] 77.0-89.1%), ≥ grade 3 trAEs incidence rate was 33.0% (95% CI 26.9-39.5%), all-grade irAEs incidence rate was 34% (95% CI 22-47%), and ≥ grade 3 irAEs incidence rate was 9% (95% CI 5-14%). Aspartate aminotransferase (AST) increase (38%, 95% CI 35-40%) is the most common trAEs. Fatigue (14%, 95% CI 7-23%) is the most common irAEs. The pooled results also showed that 18.8% (95% CI 13.2-25.2%) of patients required systemic steroid therapy due to AEs, while 6.6% (95% CI 4.6-9.0%) of patients withdrew from treatment due to AEs. Additionally, patients experiencing irAEs may have a better progression-free survival (PFS) (multivariate analysis: hazard ratio [HR] = 0.41, 95% CI 0.27-0.61, I |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink